1,2,3,4-Tetrahydroisoquinoline Hydrochloride → 1-[5-Methyl-1-(4-methyl-6-methoxy-2-pyrimidinyl)-4-pyrazolyl]-3-[4-(2-methylphenyl)-1-piperazinyl]-1-trans-propene hydrochloride
반응식
[ClH:1].CC1N(C2N=CC=CN=2)N=CC=1C(=O)CCN1CCC2C(=CC=CC=2)C1.Cl.CC1N(C2N=CC=CN=2)N=CC=1/C=C/CN1CCC2C(=CC=CC=2)C1.N1C=CC=NC=1N1C(C)=C(C(=O)C)C=N1.Cl.[CH2:70]1[C:79]2[C:74](=[CH:75][CH:76]=[CH:77][CH:78]=2)CCN1.[CH3:80][C:81]1[CH:86]=[C:85]([O:87][CH3:88])[N:84]=[C:83]([N:89]2[C:93]([CH3:94])=[C:92]([C:95](=O)[CH3:96])[CH:91]=[N:90]2)[N:82]=1.Cl.CC1C=CC=C[C:101]=1[N:106]1[CH2:111][CH2:110][NH:109][CH2:108][CH2:107]1>>[ClH:1].[CH3:94][C:93]1[N:89]([C:83]2[N:82]=[C:81]([CH3:80])[CH:86]=[C:85]([O:87][CH3:88])[N:84]=2)[N:90]=[CH:91][C:92]=1/[CH:95]=[CH:96]/[CH2:101][N:106]1[CH2:111][CH2:110][N:109]([C:74]2[CH:75]=[CH:76][CH:77]=[CH:78][C:79]=2[CH3:70])[CH2:108][CH2:107]1참가 물질
7
반응물 6
HCID 27347171,2,3,4-Tetrahydroisoquinoline Hydrochloride
HCID 122278951-(o-Tolyl)piperazine Hydrochloride
HCID 154563751-(2-Pyrimidinyl)-4-acetyl-5-methylpyrazole
HCID 220973011-[5-Methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)-1-propanone hydrochloride
HCID 220973051-[5-Methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-3-(1,2,3,4-tetrahydroisoquinolin-2-yl)-1-trans-propene hydrochloride
HCID 220973431-(4-Methyl-6-methoxy-2-pyrimidinyl)-4-acetyl-5-methylpyrazole생성물 1
실험 절차
The procedures of Example 6 (1) and (2) were repeated but substituting the 1-(2-pyrimidinyl)-4-acetyl-5-methylpyrazole and 1,2,3,4-tetrahydroisoquinoline hydrochloride employed in Example 6 (1) respectively by 1-(4-methyl-6-methoxy-2-pyrimidinyl)-4-acetyl-5-methylpyrazole and 1-(2-methylphenyl)piperazine hydrochloride. After the completion of the post treatment, the title compound was obtained.
출처 및 근거
- ORD 기록
- ord-db7af0a0c5f14de4b55a0c6772f87793
- 출처 데이터셋
- uspto-grants-1998_12
- 특허 번호
- US05852019
반응 노트
불러오는 중…